'%3e%3cpath%20id='s'%20d='M0,162.5%2022.041947,230.338137%20-35.664619,188.411863H35.664619L-22.041947,230.338137z'/%3e%3cuse%20xlink:href='%23s'%20y='-400'/%3e%3cg%20id='s5'%3e%3cuse%20xlink:href='%23s'%20transform='rotate(30)%20rotate(-30,0,200)'/%3e%3cuse%20xlink:href='%23s'%20transform='rotate(60)%20rotate(-60,0,200)'/%3e%3cuse%20xlink:href='%23s'%20transform='rotate(90)%20rotate(-90,0,200)'/%3e%3cuse%20xlink:href='%23s'%20transform='rotate(120)%20rotate(-120,0,200)'/%3e%3cuse%20xlink:href='%23s'%20transform='rotate(150)%20rotate(-150,0,200)'/%3e%3c/g%3e%3cuse%20xlink:href='%23s5'%20transform='scale(-1,1)'/%3e%3c/g%3e%3c/svg%3e)
Horizon Europe
[Horizon - Health] Personalised approaches to reduce risks from Adverse Drug Reactions (polypharmacy)
Expected to open. Consortium; UK eligible (Assoc. Country); SMEs as partners
Award
CollaborativeClosing soon
Application window
Closes: 17 September 2026 (expected) (9 days remaining)
What it funds
Expected to open. Consortium; UK eligible (Assoc. Country); SMEs as partners
Who it suits
Consortium; UK eligible (Assoc. Country); SMEs as partners
- Life sciences & health
- Industrial R&D
Programme specifications
Award band
FunderHorizon Europe
RegionUK-wide
Partners requiredYes
Next deadline17 September 2026
Key sectors
Life sciences & health
Expert guidance
We only put companies forward for competitions they can genuinely win. A free funding fit call will tell you where you stand against this programme.
Book a free consultationCheck your eligibilityMore from Horizon Europe & EU-wide
Applying for [Horizon - Health] Personalised approaches to reduce risks from Adverse Drug Reactions (polypharmacy)?
Talk to us about your grant funding plans and we will help you make it happen through effective, results-driven grant writing.
Book a free consultationFind the right grant, first time
Talk to us about your grant funding plans and we'll help you make it happen through effective, results-driven grant writing.